More than 3,000 leaders within biotechnology are registered to attend Biotech Showcase 2026 during J.P. Morgan Healthcare Week for unmatched opportunity to forge critical investment and partnering relationships as well as industry and financial media covering the event. Hosted by Demy-Colton and EBD Group, the event returns to the Hilton San Francisco Union Square January 12-14, 2026. A virtual event extends access to networking and insights January 20-21, 2026. Registration and partnering are now open for both.
Sara Jane Demy, Founder & CEO of Demy-Colton, said, “We anticipate renewed investment and dealmaking momentum in 2026, driven by rapid scientific advancement, evolving funding models, and the convergence of technology and biology. At the same time, policy changes are influencing how companies approach regulation, R&D strategy, capital deployment, and partnering. This is our 18th year for Biotech Showcase, and we’re so pleased it’s become a premier venue for dealmaking during JPM Week.”
Biotech Showcase attendees have the opportunity to:
- Engage in partnering and investment meetings among attending investors and pharma companies.
- Get to know emerging private and small-cap public biotech and TechBio companies through company presentations and partnering meetings.
- Meet with members of industry media including Endpoints, STAT, BioSpace, Fast Company, and others.
- Join curated discussions with leaders from companies like Novo Nordisk, Astellas, J.P. Morgan, Regeneron, Ipsen, Stifel, Sofinnova Investments, Cellino, Envisagenics, Syneos Health, and Angelini Ventures, among many others.
Tina Elder, Global Managing Director, EBD Group US, said, “As the premier investor conference for private and micro- to mid-cap biotechnology companies, Biotech Showcase offers unmatched opportunities for networking, dealmaking, and partnering across biotech, pharma, and the global investment community. As the industry looks toward 2026, Biotech Showcase provides a timely forum for engaging with the companies and leaders driving the industry’s evolution, offering direct exposure to emerging science, differentiated platforms, and the TechBio capabilities now essential to competitive drug development.”
Read Also: Corsera Health Announces $80 Million Series A Financing and Reaches Key Clinical Milestone
